New drug combo offers hope for patients with stubborn lymphomas
Disease control
Recruiting now
This study tests whether adding the drug ruxolitinib to the immunotherapy pembrolizumab is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. About 53 adults with Hodgkin or non-Hodgkin lymphoma will receive the combina…
Phase: PHASE2 • Sponsor: Seda S. Tolu • Aim: Disease control
Last updated May 13, 2026 15:58 UTC